Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

Published

26 March 2026

Estimated value

€16,000,000

Lots

1

Notice number

00209203-2026

Official source

Official source

CPV codes

• 73100000Servicios de investigación y desarrollo experimental

Description

This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Marburg (MARV) and/or Ebola Sudan (SUDV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development (phase 2 onwards). Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).

Frequently asked questions

What is the estimated value of this tender?

The estimated value published by the buyer is €16,000,000.

Who is the buyer of this tender?

The contracting authority is Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency (European Union).